Gilgamesh Pharma's Blixeprodil Shows Promise in Treating Major Depression: Phase 2a Results Revealed Gilgamesh Pharma has released promising topline results for their NMDA receptor antagonist Blixeprodil, showing significant antidepressant effects in patients with Major Depressive Disorder.

Gilgamesh Pharma's Blixeprodil Shows Promise in Treating Major Depression: Phase 2a Results Revealed #United_States #New_York #Major_Depressive_Disorder #Gilgamesh_Pharma #Blixeprodil